This is a single-arm, non-randomized prospective trial designed to assess the effectiveness and safety of the HistoSonics System, a novel treatment for primary or metastatic liver tumors. The trial aims to evaluate how well the system works and its safety profile in targeting liver tumors.
This Phase 1/2, first-in-human, open-label, multicenter study aims to determine the safest and most effective dose (Maximum Tolerated Dose, MTD, or Recommended Phase 2 Dose, RP2D) of LNS8801, both on its own and in combination with pembrolizumab. Using a 3+3 dose escalation design, the study will evaluate the safety, tolerability, how the drug behaves in
Brenetafusp (IMC-F106C) is an immune-mobilising monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for
This Phase 1/2a study, known as the TRESR Study, is investigating the safety, how the body processes and responds to the drug (pharmacokinetics and pharmacodynamics), and the early effectiveness of RP-3500 (camonsertib) in treating advanced solid tumours with specific genetic mutations. RP-3500 will be tested both on its own and in combination with talazoparib (a
Study of RP-3500, Camonsertib, in Advanced Solid Tumors Read More »
This is the first trial in humans to test T3P-Y058-739, a genetically modified and weakened strain of the bacterium Yersinia enterocolitica. The study aims to find the right dose, test its safety, and see how well it works in people with advanced solid tumours.
First in Human Study of T3P-Y058-739 (T3P) Read More »
DETERMINE is an open-label phase II/III trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Participants must have a cancer with an identified mutation. This could be found during routine testing or as part of another research programme.
